Corticosteroid treatment in severe patients with SARS-CoV-2 and chronic HBV co-infection: a retrospective multicenter study

[1]  G. Guyatt,et al.  A living WHO guideline on drugs for covid-19 , 2022, BMJ.

[2]  D. Annane,et al.  Risk factors for secondary hemophagocytic lymphohistiocytosis in severe coronavirus disease 2019 adult patients , 2021, BMC Infectious Diseases.

[3]  Lei Liu,et al.  Early Virus Clearance and Delayed Antibody Response in a Case of Coronavirus Disease 2019 (COVID-19) With a History of Coinfection With Human Immunodeficiency Virus Type 1 and Hepatitis C Virus , 2020 .

[4]  D. Annane,et al.  Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome. , 2020, The Journal of clinical investigation.

[5]  Lanjuan Li,et al.  Epidemiological and clinical characteristics of 70 cases of coronavirus disease and concomitant hepatitis B virus infection: A multicentre descriptive study , 2020, Journal of viral hepatitis.

[6]  Arthur S Slutsky,et al.  Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. , 2020, JAMA.

[7]  Tingyan Wang,et al.  Longitudinal changes of liver function and hepatitis B reactivation in COVID‐19 patients with pre‐existing chronic hepatitis B virus infection , 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

[8]  R. Fiorotto,et al.  Abnormal Liver Function Tests in Patients With COVID‐19: Relevance and Potential Pathogenesis , 2020, Hepatology.

[9]  S. Gates,et al.  Statistical review of Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report , 2020 .

[10]  Shusheng Li,et al.  Characteristics of Liver Function in Patients With SARS-CoV-2 and Chronic HBV Coinfection , 2020, Clinical Gastroenterology and Hepatology.

[11]  E. Buscarini,et al.  High rates of 30-day mortality in patients with cirrhosis and COVID-19 , 2020, Journal of Hepatology.

[12]  C. Ruini,et al.  Biomarkers associated with COVID-19 disease progression , 2020, Critical reviews in clinical laboratory sciences.

[13]  J. Debes,et al.  Inverse Association Between Chronic Hepatitis B Infection and Coronavirus Disease 2019 (COVID-19): Immune Exhaustion or Coincidence? , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  W. Wang,et al.  Viral and host factors related to the clinical outcome of COVID-19 , 2020, Nature.

[15]  Zhihang Peng,et al.  Dynamic relationship between D‐dimer and COVID‐19 severity , 2020, British journal of haematology.

[16]  Jian Chen,et al.  Association between ABO blood groups and risk of SARS‐CoV‐2 pneumonia , 2020, British journal of haematology.

[17]  Qingchun Yao,et al.  Retrospective study of risk factors for severe SARS-Cov-2 infections in hospitalized adult patients. , 2020, Polish archives of internal medicine.

[18]  Q. Fan,et al.  D‐dimer levels on admission to predict in‐hospital mortality in patients with Covid‐19 , 2020, Journal of Thrombosis and Haemostasis.

[19]  Lei Liu,et al.  Early virus clearance and delayed antibody response in a case of COVID-19 with a history of co-infection with HIV-1 and HCV , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  Chuan Qin,et al.  Dysregulation of immune response in patients with COVID-19 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  E. Newell,et al.  PD-1 blockade partially recovers dysfunctional virus–specific B cells in chronic hepatitis B infection , 2018, The Journal of clinical investigation.

[22]  S. Alavian,et al.  Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. , 2018, The lancet. Gastroenterology & hepatology.

[23]  Rajaa Al-Raddadi,et al.  Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome , 2017, American journal of respiratory and critical care medicine.

[24]  A. Bertoletti,et al.  Adaptive immunity in HBV infection. , 2016, Journal of hepatology.

[25]  A. Khwaja.  KDIGO Clinical Practice Guidelines for Acute Kidney Injury , 2012, Nephron Clinical Practice.

[26]  P. Pugnale,et al.  Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections. , 2011, Journal of hepatology.

[27]  Paul Garner,et al.  SARS: Systematic Review of Treatment Effects , 2006, PLoS medicine.

[28]  V. Wong,et al.  Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients , 2004, Journal of Clinical Virology.

[29]  World Health Organization,et al.  Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance , 2020, Pediatria i Medycyna Rodzinna.

[30]  V. Wong,et al.  Risk of hepatitis B surface antigen seroreversion after corticosteroid in patients with previous hepatitis B virus exposure. , 2019, Journal of hepatology.

[31]  Y. Falck‐Ytter,et al.  American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Reactivation During Immunosuppressive Drug Therapy , 2014 .

[32]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..